Literature DB >> 21541393

Metallic radionuclides in the development of diagnostic and therapeutic radiopharmaceuticals.

Sibaprasad Bhattacharyya1, Manish Dixit.   

Abstract

Metallic radionuclides are the mainstay of both diagnostic and therapeutic radiopharmaceuticals. Therapeutic nuclear medicine is less advanced but has tremendous potential if the radionuclide is accurately targeted. Great interest exists in the field of inorganic chemistry for developing target specific radiopharmaceuticals based on radiometals for non-invasive disease detection and cancer radiotherapy. This perspective will focus on the nuclear properties of a few important radiometals and their recent applications to developing radiopharmaceuticals for imaging and therapy. Other topics for discussion will include imaging techniques, radiotherapy, analytical techniques, and radiation safety. The ultimate goal of this perspective is to introduce inorganic chemists to the field of nuclear medicine and radiopharmaceutical development, where many applications of fundamental inorganic chemistry can be found.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21541393      PMCID: PMC3716284          DOI: 10.1039/c1dt10379b

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  129 in total

1.  99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals.

Authors:  S Liu; D S Edwards
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

2.  The evolution of nuclear cardiology takes us back to the beginning to develop today's "new standard of care" for cardiac imaging: how quantifying regional radioactive counts at five and 60 minutes post-stress unmasks hidden ischemia.

Authors:  Richard M Fleming; Gordon M Harrington; Riaz Baqir; Scott Jay; Sridevi Challapalli; Kayla Avery; Jim Green
Journal:  Methodist Debakey Cardiovasc J       Date:  2009

3.  Production of 66Ga and 67Ga at a compact cyclotron.

Authors:  F Szelecsényi; F Tárkányi; Z Kovács; J Bergman; S J Heselius; O Solin
Journal:  Acta Radiol Suppl       Date:  1991

Review 4.  Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides.

Authors:  Shuang Liu
Journal:  Adv Drug Deliv Rev       Date:  2008-04-23       Impact factor: 15.470

5.  Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment.

Authors:  F F Knapp; A L Beets; S Guhlke; P O Zamora; H Bender; H Palmedo; H J Biersack
Journal:  Anticancer Res       Date:  1997 May-Jun       Impact factor: 2.480

6.  Assessment of Cu-ETS as a PET radiopharmaceutical for evaluation of regional renal perfusion.

Authors:  Mark A Green; Carla J Mathias; Lynn R Willis; Rajash K Handa; Jeffrey L Lacy; Michael A Miller; Gary D Hutchins
Journal:  Nucl Med Biol       Date:  2007-04       Impact factor: 2.408

Review 7.  New directions in the coordination chemistry of 99mTc: a reflection on technetium core structures and a strategy for new chelate design.

Authors:  Sangeeta Ray Banerjee; Kevin P Maresca; Lynn Francesconi; John Valliant; John W Babich; Jon Zubieta
Journal:  Nucl Med Biol       Date:  2005-01       Impact factor: 2.408

8.  Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.

Authors:  Stig Palm; Richard M Enmon; Cornelia Matei; Katherine S Kolbert; Su Xu; Pat B Zanzonico; Ronald L Finn; Jason A Koutcher; Steven M Larson; George Sgouros
Journal:  J Nucl Med       Date:  2003-07       Impact factor: 10.057

9.  Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.

Authors:  Daniel Putzer; Michael Gabriel; Benjamin Henninger; Dorota Kendler; Christian Uprimny; Georg Dobrozemsky; Clemens Decristoforo; Reto Josef Bale; Werner Jaschke; Irene Johanna Virgolini
Journal:  J Nucl Med       Date:  2009-07-17       Impact factor: 10.057

10.  Effect of DOTA position on melanoma targeting and pharmacokinetic properties of 111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide.

Authors:  Haixun Guo; Jianquan Yang; Fabio Gallazzi; Eric R Prossnitz; Larry A Sklar; Yubin Miao
Journal:  Bioconjug Chem       Date:  2009-11       Impact factor: 4.774

View more
  23 in total

Review 1.  A brief overview of metal complexes as nuclear imaging agents.

Authors:  Douglas S MacPherson; Kimberly Fung; Brendon E Cook; Lynn C Francesconi; Brian M Zeglis
Journal:  Dalton Trans       Date:  2019-10-07       Impact factor: 4.390

2.  Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.

Authors:  Sibaprasad Bhattacharyya; Karen Kurdziel; Ling Wei; Lisa Riffle; Gurmeet Kaur; G Craig Hill; Paula M Jacobs; James L Tatum; James H Doroshow; Joseph D Kalen
Journal:  Nucl Med Biol       Date:  2013-02-27       Impact factor: 2.408

3.  Laminin receptor specific therapeutic gold nanoparticles (198AuNP-EGCg) show efficacy in treating prostate cancer.

Authors:  Ravi Shukla; Nripen Chanda; Ajit Zambre; Anandhi Upendran; Kavita Katti; Rajesh R Kulkarni; Satish Kumar Nune; Stan W Casteel; Charles Jeffrey Smith; Jatin Vimal; Evan Boote; J David Robertson; Para Kan; Hendrik Engelbrecht; Lisa D Watkinson; Terry L Carmack; John R Lever; Cathy S Cutler; Charles Caldwell; Raghuraman Kannan; Kattesh V Katti
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-16       Impact factor: 11.205

4.  Incorporation of gallium-68 into the crystal structure of Prussian blue to form K(68)GaxFe1-x[Fe(CN)6] nanoparticles: toward a novel bimodal PET/MRI imaging agent.

Authors:  Murthi S Kandanapitiye; Matthew D Gott; Andrew Sharits; Silvia S Jurisson; Patrick M Woodward; Songping D Huang
Journal:  Dalton Trans       Date:  2016-05-31       Impact factor: 4.390

5.  Preparation of clinical-grade (89) Zr-panitumumab as a positron emission tomography biomarker for evaluating epidermal growth factor receptor-targeted therapy.

Authors:  Ling Wei; Jianfeng Shi; George Afari; Sibaprasad Bhattacharyya
Journal:  J Labelled Comp Radiopharm       Date:  2013-11-13       Impact factor: 1.921

Review 6.  Porphyrins as ligands for 64copper: background and trends.

Authors:  Edgar Aguilar-Ortíz; Amir R Jalilian; Miguel A Ávila-Rodríguez
Journal:  Medchemcomm       Date:  2018-08-17       Impact factor: 3.597

7.  Non-cross-bridged tetraazamacrocyclic chelator for stable (64)cu-based radiopharmaceuticals.

Authors:  Ajit V Dale; Darpan N Pandya; Jung Young Kim; Hochun Lee; Yeong Su Ha; Nikunj Bhatt; Jonghee Kim; Jeong Ju Seo; Woonghee Lee; Sung Hong Kim; Young-Ran Yoon; Gwang Il An; Jeongsoo Yoo
Journal:  ACS Med Chem Lett       Date:  2013-07-25       Impact factor: 4.345

8.  Inorganic chemistry in nuclear imaging and radiotherapy: current and future directions.

Authors:  Valerie Carroll; Dustin W Demoin; Timothy J Hoffman; Silvia S Jurisson
Journal:  Radiochim Acta       Date:  2012-08       Impact factor: 1.440

9.  Synthesis, Cu(II) complexation, 64Cu-labeling and biological evaluation of cross-bridged cyclam chelators with phosphonate pendant arms.

Authors:  Riccardo Ferdani; Dannon J Stigers; Ashley L Fiamengo; Lihui Wei; Barbara T Y Li; James A Golen; Arnold L Rheingold; Gary R Weisman; Edward H Wong; Carolyn J Anderson
Journal:  Dalton Trans       Date:  2011-12-15       Impact factor: 4.390

Review 10.  Natural product-based radiopharmaceuticals: Focus on curcumin and its analogs, flavonoids, and marine peptides.

Authors:  Hendris Wongso
Journal:  J Pharm Anal       Date:  2021-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.